Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung

J. Z. Fuks, J. Aisner, M. Levitt

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Sixteen previously treated patients received AZQ in a phase II study to test therapeutic efficacy in refractory small cell lung cancer. The dose and schedule of AZQ was 20 mg/m2 day 1 and 8, with treatments repeated every 28 days. No objective responses were noted among 16 evaluable patients. Myelosuppression was the major toxicity. AZQ does not appear to have antitumor activity in patients with previously treated small cell carcinoma.

Original languageEnglish (US)
Pages (from-to)171-173
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume6
Issue number2
DOIs
StatePublished - 1983
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung'. Together they form a unique fingerprint.

Cite this